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Abstract 
Ultrasound Contrast Agents (UCAs) consisting of gas-filled-coated Microbubbles (MBs) with diameters between 1 and 10 mm 
have been used for a number of decades in diagnostic imaging. In recent years, submicron contrast agents have proven to be a 
viable alternative to MBs for ultrasound (US)-based applications for their capability to extravasate and accumulate in the tumor 
tissue via the enhanced permeability and retention effect. After a short overview of the more recent approaches to ultrasound- 
mediated imaging and therapeutics at the nanoscale, phase-change contrast agents (PCCAs), which can be phase-transitioned into 
highly echogenic MBs by means of US, are here presented. The phenomenon of acoustic droplet vaporization (ADV) to produce 
bubbles is widely investigated for both imaging and therapeutic applications to develop promising theranostic platforms. 
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Introduction 
The goal of nanoscale theranostics is to reach targeted tissues 
and cells for delivering any cargo of interest (drugs, proteins, 
and DNA) and visualizing in real time the actual achievement 
of the task. Nanoscale dimensions are required for internaliza- 
tion of the carrier by cells, or for trespassing of anatomical, and/ 
or functional membranes such as the skin, or the blood–brain 
barrier. Nanocarriers of different materials and characteristics 
have been so far proposed. Their design can be driven taking 
into account either the cells to be targeted or the visualization 
approach, for example, ultrasound (US),1 magnetic resonance 
imaging (MRI),2 and photoacoustic imaging (PAI).3-5 
Being sensitive to variations in density and compressibility 
with respect to the surrounding medium, traditional US ima- 
ging requires the presence of acoustical scatterers. A very large 
 
and are commercially available since 20 years. Consequently, 
the increasing interest of the clinicians for an extensive appli- 
cation in medicine pushed the US equipment producers to 
develop ad hoc imaging techniques, such as contrast- 
enhanced US, to optimize the US backscattered reflection. 
Such experience suggested the idea of manufacturing nano- 
sized carriers able to permeate tissues and then to perform some 
phase change to become visible and monitorable by US med- 
ical sonography. Retracing the history of UCAs may be useful 
to arouse new ideas for future developments. 
 
 
Ultrasound Contrast Agents 
According to the core composition, UCAs can be divided into 
three main categories: (1) gas core, (2) liquid core, and (3) solid 
deal of literature has been devoted to gas-filled microbubbles    
(MBs). As a matter of fact, MBs have been extensively used in 
the past as ultrasound contrast agents (UCAs). While their shell 
has been manufactured using different materials (polymers, 
lipids, or proteins), their core was mainly composed by inert 
and nontoxic gases, such as perfluorocarbons (PFCs), which 
have a very low solubility in blood. Many MBs were approved 
by the Food and Drug Administration (FDA) in the United 
States and the European Medicines Agency (EMA) in Europe 
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Abbreviations 
ADV Acoustic Droplet Vaporization 
APM Activation Pressure Matching 
BBB Blood Brain Barrier 
BSA Bovine Serum  Albumin 
CEUS Contrast Enhanced Ultrasound 
CHL Chlorambucil 
DAPI 40,6-diamidino-2-phenylindole 
DFB Decafluorobutane 
DFP 2H,3H-perfluoropentane 
DOX Doxorubicin 
DTX Docetaxel 
EMA European Medicines Agency 
EPR Enhanced Permeability and Retention 
ESW Extracorporeal Shock Wave 
ESWs Extracorporeal Shock Waves 
FDA Food and Drug Administration 
Gd Gadolinium 
Gd-DOTP Gd(DOTP)5-(1,4,7,10-tetra-azacyclododecane- 
N,N0,N0 0,N0 0 0-tetrakis(methylenephosphonic acid)) 
IC Inertial Cavitation 
LIFU Low-Intensity Focused Ultrasound 
MB Microbubble 
MBs Microbubbles 
MI Mechanical Index 
MRI Magnetic Resonance Imaging 
MWA Microwave Ablation 
NB Nanobubble 
NBs Nanobubbles 
ND Nanodroplet 
NDs Nanodroplets 
NIR Near-Infrared 
NP Nanoparticle 
NPs Nanoparticles 
OFP Octafluoropropane 
OLND Oxygen Loaded Nanodroplet 
OLNDs Oxygen Loaded Nanodroplets 
PA Photoacoustics 
PAI Photoacoustic Imaging 
PCCA Phase Change Contrast Agent 
PCCAs Phase Change Contrast Agents 
PCI Phase Contrast Imaging 
PEG-PCL Poly(ethylene glycol)-co-polycaprolactone 
PEG-PLLA Poly(ethylene oxide)-co-poly(l-lactide) 
PFC Perfluorocarbon 
PFCE Perfluoro-15-crown-5-ether 
PFCs Perfluorocarbons 
PFH Perfluorohexane 
PFP Perfluoropentane 
PLGA Poly(lactide-co-glycolide)-co-poly(ethylene glycol) 
PLP Prednisolone Phosphate 
PMCH Perfluoromethylcyclohexane 
PNP Peak Negative Pressure 
PTX Paclitaxel 
PVA Poly(vinyl alcohol) 
SF6 Sulfur Hexafluoride 
SPION Superparamagnetic Iron Oxide Nanoparticle 
SPIONs Superparamagnetic Iron Oxide Nanoparticles 
UCA Ultrasound Contrast Agent 
UCAs Ultrasound Contrast Agents 
US Ultrasound 
UV Ultraviolet 
contrast agents. All of them present a density and compressi- 
bility substantially different from that of blood and tissues. 
MBs belong to the first class: they have a gas core surrounded 
by a shell and their size is usually on the order of a few microns. 
Upon US application, they not only enhance US backscattering 
but they can oscillate in the sound field, producing a nonlinear 
acoustic signal enabling the selective detection of the echoes 
from the MBs from those of surrounding tissue.6 Recently, nano- 
sized bubbles have been investigated.22 Different types of liquid 
core contrast agents for US imaging have been prepared, tuning 
composition and size. Liposomes and PFC droplets are the most 
used nanoscale systems. Liposomes consist of a lipid bilayer 
with a hydrophilic liquid core. Air pockets within the lipid 
bilayer can generate acoustic reflectivity.7 Nanodroplets (NDs) 
are US-triggered phase-change contrast agents (PCCAs) and 
their unique properties are discussed in the following sections 
of this review. Finally, solid nanoparticles (NPs) such as amor- 
phous solid particles, including silica or iron oxide particles, can 
contain gas cavities in their pore structure. They showed the 
capability to generate detectable backscatter for US imaging.8 
Due to their size, nanoscale UCAs offer some advantages with 
respect to MBs, such as their ability to extravasate, providing the 
opportunity to image targets beyond the vascular system. Con- 
cerning liquid/solid UCAs, the relative incompressibility of their 
core produces a low acoustic reflectivity, making their detection 
somehow difficult. An overview on UCAs, their main properties, 
and structure is shown in Table 1 and Figure 1. 
 
MBs: From Diagnosis to Therapy 
MBs are blood pool contrast agents because they are trans- 
ported after intravenous injection in the bloodstream being 
unable to extravasate due to their size (1-10 mm).38 
According to the Rayleigh description, US backscattering 
depends on a combination of two factors: the high compressi- 
bility of the gas core and the different density with respect to 
the background. Whenever a sound wave hits such gaseous 
particles in a liquid medium, the difference between their 
acoustic impedance becomes remarkable, thus resulting in a 
stronger echo and greater acoustic energy detectable by stan- 
dard sonoghaphy. Following insonation, MBs behave as very 
efficient US scatterers: they start to compress and expand as the 
gas responds to the pressure oscillations of the acoustic 
wave.1,39 When properly modulated, US may elicit nonlinear 
acoustic signals for selective echoes detection.6 Since bubble 
deletion occurs in the bloodstream and may prevent distal 
detection, the MB stability is crucial, and since 1990, several 
types of UCAs have been developed to improve bubble life- 
time. Albunex (Molecular Biosystems, San Diego, California) 
was the first UCA available on the market in 1994. It consisted 
of air bubbles encapsulated by a human albumin shell with the 
aim of increasing stability.40 Since then, many other agents 
have been introduced in clinical practice. Currently, the major- 
ity of the UCAs has a lipid coating and contains gases with low 
diffusivity in blood to further increase bubble half-life. The 
gases used in commercially available UCAs are sulfur 
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Table 1. Overview on Contrast Agents Used in US Imaging and Their Main Properties. 
 
 Microbubble Liposome Nanobubble Nanodroplet Nanoparticle 
Core Gas (air, PFC, SF6) Hydrophilic liquid Gas (air, PFC, SF6) Liquid (PFC) Gas (PFC) 
Shell Phospholipid, polymer, protein Lipid bilayer Polymer, lipid Polymer, lipid Mesoporous silica 
Size 1-10 mm 100 nm-10 mm 200-800 nm 200 nm-1 mm 50-500 nm 
References 9-12 13-17 18-22 23-30 31-37 
Abbreviations: US, ultrasound; PFC, perfluorocarbon; SF6, sulfur hexafluoride. 
 
 
Figure 1. Schematic core–shell structure of contrast agents used in molecular US imaging (not to scale). US indicates ultrasound. 
 
hexafluoride in Sonovue/Lumason (Bracco Imaging, Milan, 
Italy),41 octafluoropropane (OFP) (C3F8) in Definity/Luminity® 
(Lantheus Medical Imaging, North Billerica, Massachusetts),42 
and decafluorobutane (DFB; C4F10) in Sonazoid (Daichii San- 
kyo, GE Healthcare, Tokyo, Japan).43 Following Albunex, a new 
albumin-based formulation was developed encapsulating OFP, 
named Optison (GE Healthcare AS, Oslo, Norway).44 However, 
albumin results in a rather thick and rigid coating,12 which limits 
bubble oscillations. On the contrary, lipid-coated bubbles, being 
the shell more flexible, allow relatively large oscillations,9 
whereas a polymer coating can increase the stability.10 Never- 
theless, polymer-coated contrast agents have more rigid shells, 
which need to be cracked in order to vaporize the oil core or let 
the gas escape, providing imaging contrast.10,11 Both lipids and 
polymers offer more options to tune the chemical and mechan- 
ical properties of the shell, also giving more opportunities for 
functionalization and targeting of the bubbles. 
Since 1990s, UCAs have attracted much research as carriers 
for drug delivery in order to transport drugs to specific diseased 
site and safely achieve the desired therapeutic effect, avoiding 
side effects. The benefit of using US in combination with MBs 
might be the delivering of the payload in a controlled way, by 
activating the release process only when the ultrasonic beam is 
switched on. Moreover, US can provide local real-time ima- 
ging.45 These features allow a more specific delivery of the 
therapeutic agents, thus reducing the undesired side effects and 
improving the efficacy. 
Generally, two modalities for drug delivery by UCAs are 
possible. In the co-administration approach, the UCAs are 
injected in the bloodstream alongside the therapeutic agent. 
Conversely, local US application can induce a transient 
 
 
Figure 2. Simplified sketch of main drug-loading techniques in 
microbubbles/nanobubbles (not to scale). Drugs can be embedded in 
the shell (1), incorporated in the core, in the case of gases or mole- 
cules soluble in PFCs (2), covalently attached to the surface (3). PFCs 
indicates perfluorocarbons. 
 
increase in endothelial cell membrane permeability, enhancing 
therapeutic agent uptake by the target cells.46,47 This method is 
also known as sonoporation. So far, several MB loading stra- 
tegies have been investigated and proposed, such as loading 
drugs into MB core, or incorporating drugs within the shell 
through covalent or noncovalent interactions (Figure 2).48 
Therefore, MBs can act as a reservoir, and the chemical prop- 
erties of the drug can affect the release kinetics.49 
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Different MB formulations have been designed to promote 
the transport of hydrophilic as well as lipophilic therapeutic 
agents. The use of US as external trigger to improve drug 
delivery efficiency has been extensively studied, as reported 
by Kooiman et al.50 
Hybrid core–shell MBs based on biodegradable cross-linked 
polymers and phospholipids were described by Capece et al.51 A 
self-assembly process starting from the preparation of liquid vesi- 
cles was tuned to obtain this system. It involved three steps: (1) the 
deposition of a phospholipid monolayer around a PFC droplet; (2) 
the addition of a hydrophilic polymer grafted with a vinyl moiety; 
and (3) the free radical photopolymerization to cross-link the 
grafted vinyl side chains. These liquid vesicles, in the presence 
of US, could successfully undergo the liquid to gas transition, 
thereby transforming the polymer vesicles into MBs. 
A variety of drug-loaded droplets able to undergo a 
US-driven phase change to gas MBs has been extensively inves- 
tigated in literature. In vitro results showed the delivery of the 
lipophilic drug chlorambucil (CHL) encapsulated by albumin/ 
soybean oil-coated microdroplets to hamster ovary cells.52 The 
authors found that incubation with the CHL-loaded NDs emul- 
sion exposed to US almost doubled growth inhibition. 
For the sake of completeness, we also report the use of MBs 
as contrast agent in other imaging applications. Interestingly, 
coupling graphene with MB surface offered the possibility to 
enhance photoacoustic signals. Paradossi et al designed an 
hybrid system, made of pristine graphene tethered to poly(vinyl 
alcohol)-based MBs and demonstrated a very good enhance- 
ment in the near-infrared (NIR) spectral region of the photo- 
acoustic signal.4 The MBs-containing Gadolinium (Gd) 
complexes can be exploited to obtain a dual imaging strategy, 
for example, phase contrast imaging and MRI.53 Superpara- 
magnetic iron oxide NP-modified MBs for US-MRI bimodality 
imaging have been proposed as well.54 
 
The Need for Smaller US-Monitorable 
Carriers 
MBs are not able to passively extravasate due to their micron- 
scaled sizes, but they remain in the circulation until they are 
taken up by the spleen and the liver55 or they dissolve in rather 
short times.56 To overcome this limitation, nanosized formula- 
tions have been designed for US-triggered drug release outside 
the bloodstream.49 In addition, MBs are too large to pass 
through the leaky vasculature of the tumor. Typically, tumor 
vessels are permeable from particles far lower than 1 mm, sug- 
gesting that the cutoff size of the pores is between 400 and 600 
nm in diameter.57 Based on these premises, targeting the tumor 
cell requires nanocarriers able to escape from the capillaries 
and enter the defective tumor microcirculation via the so-called 
enhanced permeability and retention (EPR) effect.58 This fea- 
ture can “per se” achieve drug accumulation in tumors without 
specific targeting ligands. 
Nanoscale carriers may be designed as nanobubbles (NBs) 
or NDs, depending on whether the core is gaseous or liquid at 
room temperature. However, NDs show negligible nonlinear 
acoustic contrast due to the relatively incompressible liquid 
core.59-61 Upon US, they can be phase transitioned into MBs, 
thus generating acoustic contrast locally.23,24,62 Unless a 
recently proposed procedure of “condensation” from micron- 
sized UCAs,63 NDs are normally manufactured via sonica- 
tion,28 high-shear homogenization,64 or high-speed mechanical 
agitation.52,65 Briefly, an aqueous solution or dispersion of 
coating material is emulsified by one of the techniques men- 
tioned above in the presence of liquid PFCs. The NDs typically 
result in a polydisperse size distribution. Lately, microfluidics- 
based devices have been investigated, which allow a finer con- 
trol of the droplet diameter and production rate, by controlling 
gas pressure, liquid flow rate, and device geometry.66 Sheeran 
et al described a low-temperature extrusion method to emulsify 
liquid droplets filled by DFB. Since DFB at room temperature 
is a gas, droplet generation requires that condensation occurs at 
reduced temperatures and/or increased pressures. In this study, 
droplets were first produced by condensing DFB gas at very 
low temperatures and then by encapsulating the resulting liquid 
DFB in lipid shells by membrane extrusion. A postsonication 
step can be carried out to produce NDs with a more uniform 
size distribution.24 
Sheeran et al investigated how to manufacture PCCAs con- 
taining highly volatile PFCs.26 In their work, they showed that 
DFB (boiling point 2○C) can be incorporated into meta- 
stable liquid submicron droplets with proper encapsulation 
methods. The resulting droplets are activatable with substan- 
tially less energy than other more popular PFCs. Because 
DFB is a gas at room temperature, producing liquid DFB 
droplets by using conventional techniques, such as 
microfluidics-based devices, sonication, or homogenization, 
may be a challenge. The group of Sheeran proposed an alter- 
native method of generating nanometer-sized lipid-coated 
droplets based on condensation of preformed MBs- 
containing DFB, through a combination of decreased environ- 
mental temperature and increased environmental pressure.24  
In the liquid state, the reduction in size to nanometer scale 
increases the Laplace pressure that, in turn, stabilizes the 
droplets against re-expansion at physiological temperature, 
unless an external trigger, such as US or heat, is applied. This 
method is known as “microbubble condensation” (Figure 3). 
In a subsequent investigation of MB condensation, Sheeran   
et al revealed the inherent tradeoffs involved with forming 
PCCAs from low-boiling point PFCs.67 Martin et al proposed 
to accumulate perfluorocarbon NDs in a close-packed config- 
uration and let them grow in size in situ, so that the phase- 
change conversion can occur at lower US pressures compared 
with isolated NDs.68 Cavalli et al developed perfluoropentane 
(PFP)-cored polymer–lipid-coated NBs. They are a hybrid 
system containing a phospholipid monolayer at the NB inter- 
face, coated by a polymer shell to improve stability.25 This 
type of formulation is referred to as “nanobubbles” for sake of 
simplicity, but it must be said that, prior to the US application, 
it would be more accurate to use the term “nanodroplets” 
when the core is constituted of PFP, being the PFC liquid at 
room temperature (boiling point 29○C).69 The rationale of the 
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Figure 3. The exposure of preformed PFC MBs to decreased ambient temperature and increased ambient pressure results in condensation of 
the gaseous core. The decreased size results in an increased Laplace pressure, which serves to preserve the particle in the liquid state. Once 
exposed to increased temperature and energy delivered via US, vaporization of the droplet core results in a larger, highly echogenic gas MBs. 
PFC indicates perfluorocarbon; MBs, microbubbles. Reprinted from Biomaterials, Vol. 33, Sheeran PS, Luois SH, Mullin LB, Matsunaga TO, 
Dayton PA. Design of ultrasonically-activatable nanoparticles using low boiling point perfluorocarbons, 3262-3269, Copyright (2012), with 
permission from Elsevier. 
 
hybrid lipid/polymer system is that phospholipid monolayers 
can adsorb charged polymers, such as polysaccharides 
exploiting various type of interactions.70 Moreover, the addi- 
tion of cosurfactant molecules to the phospholipid monolayer 
can play a synergic effect on the interfacial packing and sur- 
face tension. Shells of various thicknesses can be developed, 
and multilayer systems can be obtained by the layer-by-layer 
deposition method. 
NDs need to be stabilized to prevent coalescence. Most 
PCCAs are stabilized by either a single type of phospholipid,26 
a mixture of them,27 or are entirely formulated of block copo- 
lymer.28 In 2000, Kripfgans et al reported preliminary results 
for manufacturing albumin-coated droplets and studied their 
evaporation as a function of the applied acoustic pressure and 
frequency, together with a simulation predicting their lifetime 
based on gas diffusion.65 Three years later, the idea of pro- 
ducing albumin-coated and other PFC-cored microdroplets 
undergoing US-mediated cavitation was investigated by Gie- 
secke and Hynynen by in vitro determination of the inertial 
cavitation (IC) thresholds at various frequencies.70 A recent 
study by Lee et al suggested that coating the NDs with a 
protein–polymer shell can improve  their  stability.29 Capece 
et al studied the interface of hybrid shelled droplets encapsu- 
lating 2H,3H-decaperfluoropentane (DFP).30 Droplet fabrica- 
tion was based on the deposition of a dextran methacrylate 
layer onto the surface of surfactants. The droplets have been 
stabilized against coalescence by ultraviolet curing, introdu- 
cing cross-links in the polymer layer, and transforming the 
shell into an elastomeric membrane with viscoelastic beha- 
vior. Following US exposure, the DFP core of the droplets 
vaporized transforming the particles into MBs. The presence 
of a robust cross-linked polymer shell conferred an unusual 
stability also during the core phase transition and allowed the 
recovery of the initial droplet state within a few minutes after 
switching off US. 
PFCs have proven to be good candidates for liquid emul- 
sions because they have low solubility in aqueous media and 
are nontoxic in small doses.72,73 Due to their immiscibility in 
water, high-molecular weight, and low-surface tension, PFC- 
cored droplets can remain stable in circulation much longer 
than their gas-cored counterparts of similar size.74 Depending 
on the PFC of choice, the resulting half-life in vivo ranges from 
hours to days,75 which is an appealing feature for applications 
involving passive targeting and/or drug delivery. Low-boiling 
point PFCs, such as PFP, are particularly attractive because 
they allow the NDs to be designed in a metastable, 
“superheated” state from which they can rapidly turn to gas 
bubbles in response to US. Table 2 lists selected PFCs that have 
been used for ultrasonically activatable contrast agents along 
with their physical properties, whether available, collected 
from several resources of literature.76,77 Therefore, these NDs 
are often called PCCAs78 and the phenomenon is known as 
acoustic droplet vaporization (ADV). 
Finally, many solid nanocarriers have been introduced so 
far. The use of porous silica NPs to enhance the ND stability 
has been proposed as well.94 
 
Applications in Nanomedicine 
Molecular Imaging of Cancer 
One of the most important goal in tumor diagnosis is the early 
detection of cancer, for both primary tumors and metastasis. 
Two techniques can be used to achieve this goal. First, being 
tumor vasculature defective and characterized by wide fenestra- 
tions, leaking of nanocarriers makes the tumor detectable by 
imaging.95 Second, the imaging agent can be functionalized 
with specific antibodies able to identify and bind the cells over- 
expressing the cancerous phenotype. Theoretically, targeted 
NDs can penetrate the endothelial barrier and bind those tumor 
cells.96 
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Table 2. Physico-chemical Properties of Selected PFCs Used for Liquid Nanoemulsion. 
 
 
Name Abbreviations 
 
Chemical 
Formula bp (○C) 
 
Molecular 
Weight (g/mol) 
Liquid 
Density (kg/m3) 
 
Surface 
Tension (mN/m) References 
 
 
Octafluoropropanea OFP C3F8 36.7 188.02 — — 67,79 
Decafluorobutanea DFB C4F10 1.7 238.03 — — 24,26,67,79-83 
Perfluropentane PFP C5F12 29 288.03 1630 9.50 23,26,28,52,65,84-90 
Perfluorohexane PFH C6F14 56.6 338.04 1669 12.23 26,86,90,91 
Perfluoroheptane FC84 C7F16 80 388.05 1680 13.55 — 
Perfluorooctane PFO C8F18 101 438.06 1730 14.47 91 
Decafluoropentane DFP C5H2F10 55 252.05 1600 14.10 92 
Perfluoro(2-methyl-3-pentaone) PFMP C6F12O 49 316.04 — — 26 
Perfluoro-15-crown-5-ether PFCE C10F20O5 146 580.07 — — 93 
Abbreviations: PFC, perfluorocarbon; bp, boiling point. 
aPFC in gaseous state at 25○C. 
 
 
Figure 4. Schematic representation of chemotherapeutic delivery through the defective tumor microvasculature using drug-loaded ND (not to 
scale). Hydrophobic drugs can be stored in the NDs cores. The tight junctions between endothelial cells in normal tissues do not allow 
extravasation of drug-loaded NDs. In contrast, tumors are characterized by fenestrated vasculature with large gaps between the endothelial 
cells, which allows drug-loaded nanodroplets to pass and accumulate in the tumor interstitium. US causes the NDs to evaporate into MBs, thus 
locally generating acoustic contrast and triggering the release of the drug. NDs indicates nanodroplets; US, ultrasound; MBs, microbubbles. 
 
Animal model experiments have demonstrated that ADV- 
based angiography can be used as real-time monitoring of the 
effect of the ultrasonic therapy in pancreatic cancer, breast 
cancer models, and kidney function.93,97 Matsuura and col- 
leagues used quantum dots incorporated in PFC droplets to 
show that they can act as additional cavitation nuclei within 
the core and appear to significantly decrease ADV threshold.98 
They suggested the idea that NP-loaded imaging agent may 
help in spatially and temporally controlling NP deposition: this 
approach paved the way to extend ADV-based imaging to other 
applications. 
 
Therapeutic Delivery 
The therapeutic strategy based on the interaction between drug- 
loaded NDs and US was first proposed in anticancer 
chemotherapy, for which temporal and spatial control of drug 
distribution is a goal. With respect to MBs, submicron PCCAs 
represent a novel approach to achieve localized drug delivery 
due to their unique properties. The EPR effect in solid tumors 
assumes that extravasation occurs from the capillaries through 
their nanometric porous structure (Figure 4). 
Tumor therapy with drug-loaded PFC nanoemulsions com- 
bined with US was studied in vitro and in vivo. Gao et al man- 
ufactured and characterized multifunctional NPs that combine 
the properties of polymeric drug carriers, US imaging contrast 
agents, and enhancers of US-mediated drug delivery.99 At room 
temperature, the systems comprise PFC NDs stabilized by bio- 
degradable block copolymer poly(ethylene oxide)-co-poly(l-lac- 
tide) or poly(ethylene glycol)-co-polycaprolactone shell. Upon 
heating to physiological temperatures, the NDs convert into 
NBs/MBs. Following intravenous injections, a longlasting, 
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strong, and selective US contrast was observed in the tumor 
volume, indicating NB extravasation through the defective 
tumor microvasculature, suggesting their coalescence into 
larger, echogenic MBs in the tumor tissue. Under the action  
of tumor-directed US, MBs cavitate and collapse releasing the 
encapsulated doxorubicin (DOX) and dramatically enhanced 
intracellular drug uptake by breast cancer cells in vivo. Rapo- 
port et al also developed polymeric micelles to encapsulate 
liquid PFP containing DOX. Increasing the temperature to 
37○C caused the PFP nanodrops to vaporize into larger bub- 
bles. It was proposed that US focused on the tumor could 
generate larger MBs formed by coalescence of the vaporized 
NDs. The authors showed the feasibility of using polymer- 
stabilized perfluoropentane NDs to deliver DOX to breast 
cancer xenograft tumors, proving that tumor growth  could 
be arrested by  this method.19 In vitro  US-triggered delivery 
of paclitaxel (PTX) to monolayers of prostate cancer cells was 
successfully reported for lipid-coated perfluorohexane (PFH) 
NDs.86 
In a very recent paper, Cao et al introduced phase-changeable 
drug delivery NDs with programmable low-intensity focused 
ultrasound (LIFU) that could trigger drug release significantly, 
enhancing anticancer drug delivery. Based on the difference of 
acoustic pressure between soft-shelled and hard-shelled nano- 
systems, lipid-based and poly(lactide-co-glycolide)-co-poly(- 
ethylene glycol) (PLGA)-based NDs with encapsulated PFP 
and anticancer drug DOX were manufactured. By accurate 
acoustic energy deposition and coadministration of multiple 
NDs, a programmable drug-releasing profile was achieved, 
which could efficiently increase therapeutic effectiveness and 
decrease the course of chemotherapeutic treatment, as the 
authors demonstrated by both in vitro and in vivo studies.100 
The DOX-loaded acoustic phase-change NDs were developed 
for combined physical antivascular therapy and chemother- 
apy. The US stimulation can simultaneously induce locally 
vascular permeability and trigger drug release.101 Recently, 
Marano et al published that glycolchitosan NDs loaded with 
PTX or docetaxel can target taxanes to castration-resistant 
prostate cancer cell lines.102 Upon extracorporeal shock 
waves, NDs entered two different castration-resistant prostate 
cancer cells (PC3 and DU145), leading to higher cytotoxic 
and antimigration effect. 
Although most of the research was devoted to cancer, other 
applications were also investigated. Prato et al introduced a 
new platform of oxygen nanocarriers, with DFP core and dex- 
tran shell which showed good oxygen carrying capacity, and no 
toxic effects on human keratinocytes after cell internalization, 
suggesting that US-activated nanocarriers might be used to 
topically treat hypoxia-associated pathologies of the cutaneous 
tissues.92,103 Oxygen-loaded nanodroplets (OLNDs) are also 
internalized by cancer cells (eg, TUBO cells) and are localized 
only in the cytoplasm compartment (Figure 5). This result indi- 
cates that OLNDs are able to deliver their payload directly 
inside the cancer cells, minimizing the damage to the surround- 
ing healthy tissue. 
 
 
Figure 5. OLNDs internalization by TUBO cell line. TUBO cells were 
left untreated (left panels) or treated with FITC-labeled OLND PBS 
formulation (right panels) for 24 hours in normoxia. After DAPI staining, 
cells were imaged by confocal microscopy. Results are shown as repre- 
sentative images from three independent experiments. Top panels: Cell 
nuclei after DAPI staining (blue). Central panels: FITC-labeled OLND 
(green). Bottom panels: Merged images. Magnification: 63. OLNDs 
indicates oxygen-loaded nanodroplets; FITC, fluorescein isothiocyanate; 
PBS, phosphate-buffered saline; 40,6-diamidino-2-phenylindole (DAPI). 
 
Ultrasound as external trigger to enhance the gene transfec- 
tion efficiency has been investigated as well because of its safety 
and noninvasiveness for site-specific targeting, overmatching the 
other physical methods.104 Gao et al developed an US-triggered 
phase-transition cationic ND based on a novel perfluorinated 
amphiphilic poly(amino acid), which could simultaneously load 
PFP and nucleic acids.105 Cavalli et al developed a polymeric 
ND formulation, consisting of a chitosan-based shell and a PFP 
core for DNA delivery.64 To obtain a nanoscale system, tetra- 
decylphosphoric acid (C14) was added to the formulation. This 
amphiphilic molecule can localize to the PFP–water interface, 
lowering the surface tension. Chitosan was selected for the ND 
shell because of its low toxicity, low immunogenicity, and excel- 
lent biocompatibility. DNA-loaded NDs showed the ability to 
complex with and protect DNA. Transfection of COS7 cells in 
vitro was triggered by US, without affecting cell viability. 
8 
 
DP ¼ P — P ¼ ð1Þ 
 
Theranostics 
Theranostic systems provide imaging support to a therapeutic 
treatment, offering the potential to image the pathological tissues 
and simultaneously to monitor the delivery kinetics and biodis- 
tribution of a drug. The MBs/NBs have been proposed as multi- 
functional theranostic agents with the capability to provide US 
imaging and US-triggered therapy. Oddo et al designed a multi- 
modal theranostic platform based on poly(vinyl alcohol)-shelled 
MBs coupled with superparamagnetic iron oxide NPs and an 
NIR fluorescent probe (indocyanine green) in order to support 
MRI and fluorescence imaging capability.106 Various PLGA- 
shelled NB formulations have been investigated as theranostic 
system for imaging and tumor drug delivery.107-111 Rapoport  
et al have proposed a multifunctional imaging and treatment 
platform using nanosized PCCAs bearing a drug in the polymer 
shell in conjuction with drug-loaded micelles. Ultrasound, caus- 
ing the PCCAs to vaporize, enhances local drug delivery, and the 
newly formed MBs can be used to monitor “on-the-fly” the 
effectiveness of the therapeutic treatment.19 Cavalli et al devel- 
oped a chitosan-based NB formulation, containing prednisolone 
phosphate as model drug and the paramagnetic complex 1, 4, 7, 
10-tetra-azacyclododecane-N,N0,N0 0,N0 0 0-tetrakis  (methylene- 
phosphonic acid) (Gd-DOTP) as T1-MRI agent.25 In a recent 
work, porphyrins were combined with pluronic NBs to obtain an 
US-activated theranostic agent that exploits the sonodynamic 
activity in vitro.112 Recently, cell-penetrating peptide targeted 
10-hydroxy camptothecin-loaded lipid NPs were combined with 
LIFU for precision theranostics against hepatocellular carci- 
noma. A hyaluronic acid-mediated tumor accumulation was 
observed and after irradiation by LIFU, NPs turned into MBs 
by ADV, thereby enhancing US imaging and promoting local 
release of antitumor drug.113 
 
 
The Physics of ADV 
The physical principles underlying ADV have not been com- 
pletely clarified yet. Concerning the basic thermodynamics, in 
any closed system at a given temperature, the vapor pressure is 
defined as the pressure at which the liquid phase of a substance 
is in equilibrium with its vapor phase. 
When the surrounding pressure is larger than the vapor 
pressure, the liquid substance remains in its condensed form. 
Conversely, when the surrounding local pressure drops below 
the vapor pressure, the liquid molecules will quickly escape 
from the gas phase (boiling) without any necessary changes  
in temperature.114 The acoustic waves can modify the local 
pressure of the liquid, thus triggering the phase transformation, 
either from liquid to gas or backward from gas to liquid. 
 
The Role of the Laplace Pressure 
Being the ND a confined system, it experiences a Laplace pressure, 
which is defined as the pressure upon the interior fluid generated by 
the surface tension (or interfacial energy) between the two immis- 
cible phases that compresses the liquid or gas inside the droplet: 
 
 
Figure 6. Schematic plot showing the vaporization of the liquid 
droplet as soon as the local acoustic pressure drops below the pres- 
sure difference between the vapor pressure and the Laplace pressure 
(not to scale). 
 
 2g 
inside outside  rðtÞ 
where Pinside and Poutside indicate the pressure inside and outside 
a droplet, respectively, g is the interfacial tension, and r(t) is the 
droplet radius. The hydrophobicity of liquid PFCs leads to 
relatively high interfacial surface tension when dispersed in 
water. During the phase of rarefactional acoustic pressure, the 
pressure within the PFC droplet drops below the vapor pressure 
of the PFC (called “subpressurization”): this event allows the 
liquid to transiently vaporize and condense back again at larger 
acoustic pressure (Figure 6). However, because the Laplace 
pressure is an inverse function of the radius, expansion of dro- 
plets in the nanometer range occurs less easily than in the 
micrometer range. NDs may experience Laplace pressures of 
the order of some atmospheres and actually PFC droplets 
injected in vivo do not vaporize spontaneously and hence their 
boiling point increases.41 Lower boiling point PFCs, such as 
PFP, enable vaporization using lower acoustic amplitude.42 
Furthermore, liquid droplets immiscible in the surrounding 
liquid medium, because of the Laplace pressure, can experi- 
ence “apparent superheating” and thus will never turn to a gas 
bubble if encapsulated by a nanoscale shell. 
Finally, other authors reported subpressurization of liquid 
PFC droplets with no gas formation.19,28,65,82 This phenom- 
enon could be referred to “apparent subpressurization” (analo- 
gous to the apparent superheating) in which the Laplace 
pressure was sufficiently large that the vapor pressure at a 
temperature above the normal boiling point was still not greater 
than the local pressure inside the droplet. This may be due to 
the absence of a nucleation event.114,115 
 
The Impact of the US Parameters 
Much discussion in the literature has been devoted to the 
mechanisms forcing a droplet to undergo a phase transition 
when US is applied and, in particular, to define its threshold. 
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ADV will be favored by increasing US frequency, pulse 
length, and peak-negative pressure (PNP) of the acoustic wave 
and by decreasing the Laplace pressure (both due to lower 
surface tension or larger droplet radius). Several authors 
experimentally confirmed these findings.71,79,116 All these fac- 
tors should be taken into account to optimize ADV process. 
The relation between ADV and IC threshold, that is, when the 
sudden expansion and then rapid collapse of a gas bubble in 
response to a PNP occurs, was investigated by different 
groups.71,91,117-119 Their experiments focused on albumin- or 
lipid-coated microdroplets and demonstrated that the ADV 
threshold was lower than the IC threshold, meaning that the 
droplet-to-bubble transition occurs in less extreme conditions 
than those required for IC. The IC threshold was monitored 
through passive acoustic detection of albumin-coated microdro- 
plets loaded with different PFCS, including those with boiling 
point higher than that of PFP (ie, PFH and perfluoromethylcy- 
clohexane).71 The PFC droplets of higher molecular weights and 
boiling points did not show larger IC threshold and thus super- 
heating is not required to cavitate the droplets with US bursts.71 
This result was later confirmed by Rapoport et al in experiments 
with perfluoro-15-crown-5-ether NDs: the US pressures required 
to trigger their vaporization were only slightly higher than those 
for PFP NDs.93 Kawabata et al proposed to use the sequential 
phase shifting of multiple liquids with different boiling points.119 
They considered NDS containing a mixture of PFP and DFP that 
could be vaporized at diagnostic US frequency: by changing the 
ratio of DFP to PFP, the US intensity required to induce sono- 
graphically significant vaporization changed. The authors 
hypothesized that vaporization of DFP with higher boiling point 
was favored by the fact that PFP was already vaporized.119 In 
2009, Rapoport et al showed that indeed US-induced droplet-to- 
bubble transition was substantially catalyzed by large preexist- 
ing bubbles irradiated by low-frequency US.28,120 These results 
suggested a new strategy for improving the efficiency of droplet- 
to-bubble transition not only by mixing PFCs of different boiling 
point but also by using polydisperse droplet size distributions. 
 
 
Other Open Problems 
The main reason why the physical mechanisms of ADV still 
remain elusive relies in the large mismatch between the US 
wavelength and the droplet size. Nevertheless, such discre- 
pancy may be overcome by a new recently proposed mechan- 
ism.121 This study reveals that ADV is initiated by a 
combination of two phenomena: highly nonlinear distortion  
of the acoustic wave before it hits the droplet and focusing of 
the distorted wave by the droplet itself. At high excitation 
pressures, nonlinear distortion causes the formation of super- 
harmonics, whose wavelengths are of the order of magnitude of 
the droplet size. These superharmonics strongly contribute to 
the focusing effect; therefore, the proposed mechanism also 
explains the observed pressure thresholding effect. This inter- 
pretation was validated with experimental measurements of the 
positions of the nucleation spots captured with an ultrahigh- 
speed camera, and an excellent agreement with the theoretical 
prediction was observed. 
Another critical issue depends on the initial vapor nuclea- 
tion required for ADV to occur. The basic explanation for the 
formation of a gaseous nucleus in an infinite liquid is provided 
by the homogeneous nucleation theory. It is usually assumed 
that the initial cavity formation takes place instantaneously.122 
Due to this very fast transition and the extremely small size of 
the initial vapor seed (on the order of 10 nm),89 the nucleation 
pocket may entirely vaporize the droplet before the event 
becomes observable with the detection systems currently avail- 
able. Experimental results actually show that some time is 
required: the probability of homogeneous nucleation of a grow- 
ing gas bubble is proportional to the time window (at constant 
subpressurization) and increases exponentially with the magni- 
tude of subpressurization. In 2016, Mountford and Borden 
pointed out that the mechanism of homogeneous nucleation 
may be an alternative explanation for the metastability of 
superheated NDs. Interestingly, they compared the homoge- 
neous nucleation theory with some ADV results,123,124 show- 
ing that a possible explanation was due to the subharmonic 
focusing of the incident US waves at the droplet–water inter- 
face,121,125 which would increase the local PNP experienced 
within the droplet and facilitate the phase transition. 
 
Theoretical Modeling 
Theoretical modeling of ADV has been carried out as well. One 
of the first analytical approaches has been proposed by Qamar 
et al,126,127 who modeled bubble evolution from microdroplets 
contained in a rigid tube. Their results were compared with the 
experimental data of Wong et al for PFP droplets.125 The simu- 
lations by Qamar et al showed an interesting pattern by which 
under certain conditions, droplet evolution may be character- 
ized by an overexpansion and oscillatory settling to a final 
diameter. Moreover, they assumed that the PFC mass evapora- 
tion rate was constant over the entire process of vaporization, 
which is a strong simplification, especially when the ambient 
pressure changed in response to the applied US field. Addition- 
ally, Qamar et al used the ideal gas law for describing the vapor 
bubble. More recently, Shpak et al proposed a simple model to 
describe the growth of a vapor bubble inside a PFP droplet,128 
hypothesizing that the vapor temperature inside the bubble is 
constant and equal to the boiling point for PFP (29○C at atmo- 
spheric pressure), and the bubble growth is driven by heat 
transfer from the surrounding liquid medium which has a tem- 
perature higher than that within the bubble. To compute the 
heat transfer, Shpak et al assumed a temperature gradient only 
within a thin (relative to the bubble radius) thermal boundary 
layer, whose thickness increases proportionally to the square 
root of time.129,130 To take into account for the impact of US, 
they also included an effect called “rectified heat transfer.”131 
In another study, Shpak et al132 modeled the growth of a vapor 
bubble by numerically solving the Keller-Miksis equation133 in 
combination with the standard partial differential equations, 
describing the temperature field in the surrounding liquid, the 
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heat transfer between the bubble and the liquid, and the gas 
diffusion through the bubble surface.134 Regarding thermal 
processes, their model reproduces the approach used by Hao 
and Prosperetti for vapor bubbles in ordinary liquids.135 Both 
models of Shpak et al assume that a vapor bubble is embedded 
in an infinite medium of liquid PFP, preventing the study of the 
bubble oscillations. The droplet-to-bubble transition has been 
modeled by Pitt et al who proposed a modification of the 
Rayleigh-Plesset equation.136 Conversely to the models men- 
tioned above, they considered a vapor bubble formed around a 
PFC droplet immersed in water, that is, the gas bubble forma- 
tion initiates as a spherical vapor layer between the droplet 
surface and water and consists of a mixture of PFC and water 
vapor. 
 
US Imaging Applications of ADV: Limitations 
and Perspectives 
Many strategies using nanoscale systems have been proposed 
in order to improve the current formulations. As a matter of 
fact, some critical issues related to ADV at the nanoscale 
should be taken into account for future diagnostic and thera- 
peutic applications. According to Laplace law, the smaller the 
droplet, the larger the internal pressure, thus increasing the 
saturation pressure required to trigger the droplet-to-bubble 
transition to higher temperature and acoustic pressure that are 
potentially harmful in clinical applications. The problem has 
been handled using different strategies ranging from droplet 
design to optimization of the US activation parameters. 
In order to prevent the increase in ADV thresholds that 
occurs when the droplet size decreased, the use of volatile PFC 
has been proposed. The advantage in the vaporization thresh- 
olds obtained by increasing PFC volatility is, however, coun- 
terbalanced by a decrease in thermal stability (as the 
vaporization pressure and temperature are governed by the 
Clausius-Clapeyron relation). The stability of NDs can be 
improved with surfactant or stabilizing agent in the external 
media,19,28,96,96,137 but the in vivo stability is still critical, due 
to the rapid dilution of the surfactants upon injection. In an 
early study by Kawabata et al, the authors showed that the 
ADV threshold can be finely tuned by mixing miscible PFC.119 
Some years later, Sheeran et al manufactured droplets com- 
posed of 1:1 mixture of DFB and OFP and showed that the 
resulted droplets had intermediate vaporization thresholds as 
well as intermediate stability.67 Another strategy to lower the 
phase-transition threshold is to increase the size of the 
NDs.71,116,118 Larger droplets are characterized by smaller 
Laplace pressure138 and are more easily vaporized into bubbles 
at lower pressure with respect to nanoscale droplets.26,97,139,140 
Decreasing the US pressure threshold has been explored by 
changing the US parameters in terms of frequency65,117 or 
pulse length.118 Minimizing the mechanical index is often pre- 
ferred in order to circumvent undesired side effects, but this can 
compromise the activation of the PCCAs in the acoustic field at 
depth due to attenuation. A technique called activation pressure 
matching has been proposed by Rojas et al to deliver the 
required pressure in order to produce uniform ND vaporization 
and to limit the delivered amount of energy.141 They showed 
that such approach increases the time needed by a single bolus 
of NDs to generate useful contrast and to provide consistent 
image enhancement in vivo. Interestingly, Lin et al investi- 
gated the contrast enhancement produced by ultrasonically 
activatable PCCAs, either free or confined in a microvessel   
or microchannel phantom after US application.142 Their experi- 
mental results indicated more than 1 order of magnitude less 
acoustic vaporization in a microchannel than that in a free 
environment taking into account the attenuation effect of the 
vessel on the MB scattering. This finding may improve the 
knowledge and the understanding in the applications of PCCAs 
in vivo. 
Beside US, microwave-activated ND vaporization was 
investigated to overcome the critical issues of traditional ADV. 
Novel folate-targeted lipid-shelled NDs cored with a mixture of 
PFCs (ie, PFH, PFP) were prepared for highly efficient percu- 
taneous US imaging-guided microwave ablation of tumors.143 
Much research has been devoted to the possibility of visua- 
lizing the NDs or inducing their vaporization adding other 
imaging modalities to US. Concurrent optical observation and 
PAI are the most popular approaches,81,83,144,145 together with 
the use of surfactants detectable with MRI.146,147 Interestingly, 
phase-change agents have been recently proposed as promising 
photoacoustic contrast agents. Highly absorbing optical con- 
trast agents, such as gold NPs, can be encapsulated in MBs and 
NBs for multimodal imaging contrasts. Gold nanospheres have 
been encapsulated in bovine serum albumin shell of PFC dro- 
plet to obtain a dual-contrast agent capable of providing image 
contrast enhancement for both US and PAI modalities.148 Other 
authors reported the preparation of gold NP-templated MBs, 
filled with various PFC gases, that can generate NDs by a 
condensation approach.149 
Very recently, NDs production from homemade, preexisting 
MBs, based on the use of cosolvents150 or the acoustic destruc- 
tion of MBs,151 has been described by many researchers. 
A very appealing idea for future development consists in 
manufacturing PCCAs directly from already commercially 
available MBs, such as Definity (Lantheus Medical Imaging)152 
and MicroMarker (Bracco, Geneva, Switzerland and VisualSo- 
nics, Toronto, Canada).63 This strategy is very promising since 
off-label use of commercially available MBs may be simpler 
than obtaining FDA or EMA authorizations ex novo. 
It is worth noting that the interaction of US pulses with the 
drug-loaded MBs produced by ADV involves a number of 
mechanisms, such as acoustic cavitation, heating, radiation 
forces, and sonoporation.153 Stable bubble cavitation generates 
strong shear stress close to the bubble surface, thus impacting 
on cell membranes. The IC produces shock waves and high- 
speed microjets, which also disrupt cell membranes. The tran- 
sient increase in cell membrane permeability allows the uptake 
of drugs, genes, and peptides from a variety of carriers (poly- 
meric micelles, liposomes, and nanoemulsions).114 
Intriguingly, the internalization of targeted or nontargeted 
drug-loaded droplets into cells and the subsequent vaporization 
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could lead to new tissue-specific therapy, allowing the con- 
trolled release of drugs directly to the diseased cells. Studies 
have shown that lipid-coated MB and liquid PFC droplets can 
be internalized into neutrophils, macrophages, and tumor 
cells.154-157 Preliminary investigations from Kang and col- 
leagues demonstrated the PCCA uptake into peritoneal 
macrophages.157 
 
Conclusions 
In summary, future design of theranostic platforms should 
address many challenges, such as good visualization, high pay- 
load, target delivery, and toxicity issues. A number of nanos- 
tructures have been developed as effective US imaging tools. 
Among them, PCCAs might be interesting as multifunctional 
systems for their specific physicochemical properties and flex- 
ible composition. However, further understanding of the NDs 
behavior as well as the physical mechanisms of ADV either in 
vitro or in vivo is still needed for the clinical translation. 
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